Cfhmetal - the classification of buys & sells is hopelessly inaccurate.
Otherwise, as I said before, the share price would hardly be down over 6% on a day when buy outnumbered sell volume.
PompeyMagnus - presumably those "chunky buys" were outweighed by chunky sells, seeing as the share price was down over 6% today.
bigbench - as a holder myself, i like your optimism. but methinks it is just that at this stage.
dividends are only likely to be forthcoming if the appraisal well - & subsequent drills - prove successful.
it's kinda a **** or bust share.
Andrew7 - the only "celeb" I can think of who might prove a decent fit is Steven Bartlett. IMHO, most so-called celebrities & influencers are nothing much more than vacuous airheads.
Problem is, I suspect you'd get a lot lower conversion than 1%. And Steven Bartlett's fee would probably wipe out all the profit. And some.
Easy enough to buy £10K on iweb at 11.58am.
I didn't deal, as I've already bought what I want, but they were quoting 27.28p.
EGTP - playing devil's advocate for a moment. But someone had to sell the shares at that price to Oberon. And we doj't know who that someone was.
So even if Oberon regard HEX as "cheap as chips", someone else reckoned it was time to man the exits.
I'm a Hex holder, but I don't think you can read much into Oberon's accumulation. They may be right, they may not. Nobody knows, as nobody has the results of the drill yet.
You’ve gotta hand it to the chartists. They got this latest share price movement spot on.
Oh wait, I was holding the graph upside down.
Frits - bet he's quaking in his boots now, waiting at the window for those flashing blue lights & ominous knock on the door.
Andrew67 - I suspect your suggestion was tongue in cheek. But just in case, there are a few teensy problems with it:
1. In terms of Opti's bottom line, you'd be better off buying direct. Rather than via Amazon (where Opti has to pay a hefty commission). Though of course this wouldn't then boost Opti's ranking on Amazon.
2. What on earth's anyone gonna do with a grand's worth of Opti stock?
3. I suspect a lot of private investors on this board are LTHs who bought in at much higher prices than today's. So any share price recovery will boost their coffers far less than you suggest.
Other than that, brilliant idea.
Quilver - sounds like you haven't seen my previous posts.
It's quite clear what's "holding Tek down".
Nothing to do with the MMs. Everything to do with Tek having no obvious way of crystallising value in any of its holdings. Remember those special dividends we were promised when Tek's holdings floated & gained independence? Well, we're still waiting.
Three of Tek's "incubators" have now IPO'd (Bell, Lucy & Microsalt). Two are way down on their launch price. Microsalt is currently way up, but has recently said "the rollout of MicroSalt across new and/or further B2B product lines has been slower than hoped during the current year to date".
So it's anyone's guess how well Microsalt's SP will hold up between now & the earliest Tek can sell any of its stake there. For reasons best known to itself, Tek locked itself into Microsalt for 12 months from IPO. So any current gains are paper-only for now.
Do I see the TURN DOWN happening? , some interesting prices are appearing at the moment
spread 29.00 v 29.15p
So much for your charts.
Nolupus - I see you're being disingenuous (again) saying "paper loss of roughly £850k on the sale of the Incanthera shares".
As has previously been pointed out, given IMM's low cash position, it had to raise funds SOMEHOW if it was to exercise the 7.3m Incanthera warrants at 9.5p each which are due to expire in September.
Sure, it may not have got top dollar by selling when it did. But you could argue part/most of the subsequent rise in Incanthera's share price was directly due to the disposal of IMM's stake.
As it is, IMM has raised sufficient funds to boost its cash reserves by around 800k AND to fund the 7.3m warrants. Its resulting Incanthera share stake will be even further in the money now too.
Also, IMM doesn't have to sell the Incanthera shares exercised via this warrant any time soon if it feels they've further to rise.
I’ll stick to the seaweed & tealeaves thanks.
Despite HEX being VERY different from HE1 (in operational costs, so capital requirements), today's heavily discounted HE1 placing has undoubtedly dented HEX sentiment too.
I say that, because I can't find anything untoward in this morning's Scoping Study RNS.
Of course, UK markets in general are down this morning too, which may not be helping.
Any investors (who haven't already) will soon clock the major differences between these two companies. And I suspect some will promptly jump ship from HE1 to HEX, wishing they'd acted sooner.
Closer to SOME form of news, possibly.
Whether it's "the news we want to hear" is still anyone's guess.
Alessandro - me neither.
Especially when it suggests "now should be the time to bounce back" on the very day the share's DOWN (as I write).
You'd be better off asking your pet gerbil for investment tips IMHO.
FriedmanSowell - It’s sales. So will be pre- any commission/influencer costs.
Still a decent revenue stream though, as Opti should get the lion’s share.
Leistertheinvestor - there’s a reason why the FDA suggests their preferred trial protocol. And I think it’s safe to assume it stems from their vast experience of previous comparable trials.
Of course, every trial is different and IMM is perfectly within its rights to say it wants a different design. I suspect this was motivated as much by speed (& cost) as the likelihood of a better readout, though obviously all parties ultimately want it to succeed.
My understanding is that the FDA wouldn’t normally prevent ANY trial design from proceeding, unless they had concerns on patient safety grounds. So in this instance, IMM would have been free to proceed. After all, it’s their (our!) money. But IMHO that doesn’t mean it convinced the FDA their alternative trial design was better - or even as good - as a Phase 2/3 adaptive clinical trial.
PJMaaa - there certainly does appear to be resistance around £9.
But it doesn't largely seem to be "thanks" to any widening NAV discount. Give or take 2-3%, that's remained fairly stable since April.
I guess what may be needed to move the sentiment dial is for one or more of SMT's private holdings to stage a successful IPO.
SpaceX? Well maybe not an IPO just yet. But in May 2024, Bloomberg reported SpaceX plans to sell shares at $108 to $110 apiece in a tender offer that could value the company at roughly $200 billion.
GoldGirl - Immupharma HASN'T fully gone "in line with FDA suggestions" as you suggest.
Their "recommendation" was for a Phase 2/3 adaptive clinical trial and IMM initially agreed to this. Before subsequently changing their mind & opting for a Phase 3 study including dose range.
It's rarely sensible to go against FDA guidance, but we'll see.